Hormonal Contraception - Pharmacology

SECTION 1

Historical Context & Motivation

The development of hormonal contraception stands as one of the most consequential pharmacological achievements of the twentieth century. Before the advent of reliable hormonal agents, fertility control relied largely on barrier methods and behavioral strategies that carried high failure rates. The realization that exogenous steroid hormones could suppress ovulation opened an entirely new therapeutic paradigm, one that demanded integration of reproductive endocrinology, synthetic chemistry, and clinical pharmacology. Understanding how this field evolved illuminates the mechanistic rationale behind every modern contraceptive formulation and underscores why pharmacological intervention at the hypothalamic-pituitary-ovarian (HPO) axis remains the cornerstone of reversible birth control.

1921 • Haberlandt's Ovarian Extract Experiments

Ludwig Haberlandt demonstrated that transplanting ovaries from pregnant rabbits into non-pregnant animals induced temporary infertility, providing the first experimental proof that ovarian hormones could suppress fertility.

1951 • Synthesis of Norethindrone

Carl Djerassi synthesized norethindrone, the first orally active progestin. This 19-nortestosterone derivative retained progestational activity while resisting first-pass hepatic metabolism, enabling oral administration.

1960 • FDA Approval of Enovid

The first combined oral contraceptive pill (COC), containing 150 µg mestranol and 9.85 mg norethynodrel, received FDA approval. Its high estrogen dose was later recognized as the source of significant thromboembolic risk.

1990s • Third-Generation Progestins and Low-Dose Formulations

Development of desogestrel and gestodene reduced androgenic side effects. Ethinyl estradiol (EE) doses decreased to 20–35 µg, drastically lowering cardiovascular risks while maintaining contraceptive efficacy.

2010s • Natural Estrogen and Novel Delivery Systems

Formulations incorporating estradiol valerate and estetrol emerged, aiming to further reduce metabolic and coagulation impacts. Long-acting reversible contraceptives (LARCs) such as the etonogestrel implant and levonorgestrel IUS gained prominence for their superior adherence profiles.

The central pharmacological question that this lesson addresses is: How do synthetic estrogens and progestins exploit negative feedback on the HPO axis to achieve reliable anovulation, and how do differences in formulation, dosage, and delivery route shape efficacy, safety, and side-effect profiles? Answering this question requires understanding receptor pharmacology, pharmacokinetics, and the clinical reasoning that guides contraceptive selection.

SECTION 2

Core Principles of Hormonal Contraception

Hormonal contraception operates through several interdependent mechanisms, all ultimately traceable to the pharmacological properties of synthetic estrogens and progestins. While suppression of ovulation is the primary mechanism of action for combined formulations, redundant mechanisms at the level of the cervix, endometrium, and fallopian tubes provide additional layers of protection. The following principles form the foundation of hormonal contraceptive pharmacology.

HPO Axis Negative Feedback

Exogenous estrogen and progestin suppress pulsatile GnRH release from the hypothalamus. This in turn reduces anterior pituitary secretion of FSH and LH, preventing the mid-cycle LH surge that triggers ovulation.

Cervical Mucus Alteration

Progestins thicken cervical mucus, producing a dense, cellular plug that impedes sperm migration into the upper reproductive tract. This mechanism is particularly important in progestin-only methods, where ovulation may not be consistently suppressed.

Endometrial Atrophy

Continuous progestin exposure transforms the endometrium into a thin, decidualized state that is unreceptive to implantation. This effect accounts for the reduction in menstrual bleeding observed with many hormonal methods and serves as a secondary contraceptive mechanism.

Tubal Motility Modification

Progestins may alter ciliary beat frequency and smooth muscle contractility within the fallopian tubes, disrupting oocyte transport. While less studied, this provides an additional layer of contraceptive efficacy.

Receptor Selectivity and Off-Target Effects

Synthetic progestins vary in their affinity for androgen, glucocorticoid, and mineralocorticoid receptors. This cross-reactivity determines side-effect profiles, including acne, weight gain, and mood changes, and guides clinical selection of specific formulations.

✦

KEY TAKEAWAY

Think of the HPO axis as a thermostat-controlled heating system. Endogenous estrogen and progesterone are like the room temperature that the thermostat monitors; when the system senses adequate hormone levels via negative feedback, it turns the 'heater' (GnRH → FSH/LH → ovulation) off. Administering exogenous hormonal contraceptives is analogous to placing a warm lamp next to the thermostat sensor: the system reads a falsely elevated signal, keeps the heater off, and ovulation never occurs. Different formulations essentially vary in how strongly and consistently they 'trick' the thermostat.

SECTION 3

The HPO Axis and Hormonal Contraception

The diagram illustrates the HPO axis from hypothalamus (top, violet border) through the anterior pituitary (cyan border) to the ovary (pink border). The endogenous negative feedback loop is shown in green dashed lines on the left. Red dashed inhibitory arrows on the right depict the site of action of exogenous hormonal contraceptives, which suppress GnRH pulsatility and gonadotropin secretion. The bottom panel summarizes the three secondary contraceptive mechanisms.

The diagram above captures the central pharmacological strategy of hormonal contraception. In the physiological state, GnRH neurons in the arcuate nucleus of the hypothalamus fire in a pulsatile fashion, driving anterior pituitary gonadotropes to release FSH and LH. The mid-cycle LH surge is triggered by a transient switch from negative to positive estrogen feedback when estradiol levels exceed ≈ 200 pg/mL for 50 or more hours. Combined hormonal contraceptives abolish this surge by maintaining steady-state exogenous estrogen and progestin levels that lock the HPO axis in its negative-feedback mode. Progestin-only methods primarily act via the secondary mechanisms shown in the lower panel—cervical mucus thickening and endometrial atrophy—though higher-dose progestin-only methods (e.g., DMPA) also suppress ovulation.

SECTION 4

Pharmacological Mechanisms in Depth

Estrogen Component: Pharmacology and Rationale

The estrogen component of combined hormonal contraceptives serves three critical functions. First, it provides potent suppression of FSH, preventing follicular recruitment and maturation. Second, it stabilizes the endometrium, reducing breakthrough bleeding that would otherwise occur with progestin-only exposure. Third, it potentiates the progestin effect on the endometrium by upregulating progesterone receptor expression. Ethinyl estradiol (EE) remains the most commonly used synthetic estrogen in COCs. The 17α-ethinyl group protects it from first-pass hepatic metabolism, conferring high oral bioavailability (approximately 40–50%). However, EE also robustly induces hepatic synthesis of clotting factors (II, VII, X, fibrinogen), sex hormone-binding globulin (SHBG), and angiotensinogen, which underlies the elevated thromboembolic and hypertensive risks associated with COC use.

Progestin Component: Receptor Cross-Reactivity

Synthetic progestins are classified by their parent compound: 19-nortestosterone derivatives (estranes and gonanes) and 17α-hydroxyprogesterone derivatives (pregnanes). Each progestin exhibits a unique receptor-binding profile across progesterone (PR), androgen (AR), glucocorticoid (GR), and mineralocorticoid (MR) receptors. This cross-reactivity determines the clinical side-effect profile. For example, levonorgestrel possesses significant AR agonist activity, which may contribute to acne and hirsutism, while drospirenone exhibits MR antagonist activity (anti-aldosterone effect), offering a favorable profile for patients prone to fluid retention.

Progestin	Generation	PR Agonism	AR Activity	GR Activity	MR Activity
Norethindrone	1st	+	+ (agonist)	±	None
Levonorgestrel	2nd	++	++ (agonist)	None	None
Desogestrel	3rd	++	+ (agonist)	None	None
Drospirenone	4th	++	Anti-androgenic	None	Antagonist
Dienogest	4th	++	Anti-androgenic	±	None

Receptor-binding profiles of selected progestins. +/++ indicates relative agonist potency; ± indicates minimal activity.

Pharmacokinetic Considerations

The efficacy of hormonal contraceptives depends critically on maintaining plasma drug concentrations above the threshold required for ovulation suppression. For EE-containing COCs, the steady-state trough level of EE must remain sufficient to suppress FSH-driven folliculogenesis throughout the active pill phase. The hormone-free interval (HFI)—traditionally seven days in 21/7 regimens—permits a decline in serum hormone levels, during which follicular recruitment may begin. If the HFI is extended (e.g., by missed pills at the start or end of the pack), the risk of escape ovulation increases substantially. This pharmacokinetic principle underlies the clinical recommendation that missed pills at the beginning or end of the active phase are the most dangerous because they effectively lengthen the HFI.

PEARL INDEX (CONTRACEPTIVE FAILURE RATE)

Pearl Index = (Number of unintended pregnancies × 12 × 100) ÷ (Total months of exposure)

The Pearl Index estimates the number of unintended pregnancies per 100 woman-years of use. For COCs, the perfect-use Pearl Index is ≈ 0.3, while the typical-use rate is ≈ 7–9 due to non-adherence. LARCs such as the etonogestrel implant achieve Pearl Indices below 0.1.

SECTION 5

Classification of Hormonal Contraceptive Formulations

Hormonal contraceptives span a wide range of formulations and delivery systems, each with distinct pharmacokinetic profiles, efficacy rates, and clinical niches. Understanding this classification is essential for patient counseling and rational prescribing. The major categories include combined hormonal contraceptives (CHCs)—which contain both an estrogen and a progestin—and progestin-only contraceptives (POCs), which omit the estrogen component entirely and are therefore suitable for patients with contraindications to estrogen.

Hierarchical classification of hormonal contraceptive methods. Combined methods (left, cyan borders) include COCs, transdermal patch, and vaginal ring. Progestin-only methods (right, pink borders) include POPs, injectable DMPA, the subdermal etonogestrel implant, and the levonorgestrel intrauterine system (LNG-IUS). The bottom panel ranks methods by typical-use first-year failure rate, illustrating the adherence advantage of LARCs.

COC Dosing Regimens

COC formulations are further stratified by their dosing pattern across the cycle. Monophasic regimens deliver a constant dose of estrogen and progestin during all active pills, simplifying use. Biphasic and triphasic formulations vary the estrogen-to-progestin ratio across the cycle, ostensibly mimicking physiological fluctuations, though clinical evidence of superior outcomes is limited. Extended-cycle regimens (e.g., 84/7 or continuous 365-day use) shorten or eliminate the hormone-free interval, reducing withdrawal bleeding episodes and, importantly, decreasing the window for escape ovulation. The pharmacological rationale for shortening the HFI is compelling: fewer pill-free days means less opportunity for follicular rescue and a wider margin of safety for missed doses.

SECTION 6

Worked Example: Selecting and Counseling on a Hormonal Contraceptive

The following worked example illustrates the clinical reasoning process for selecting an appropriate hormonal contraceptive, integrating pharmacological principles with patient-specific considerations.

Clinical Scenario: Contraceptive Selection for a 28-Year-Old Patient

1
Step 1 — Gather Patient History

A 28-year-old woman presents requesting contraception. She reports a history of migraine with aura, a BMI of 24 kg/m², no history of VTE, is a non-smoker, and has been experiencing troublesome acne. She desires a method that is highly effective but prefers to avoid daily pills. Key pharmacological considerations include the migraine with aura history and the desire for acne improvement.

Migraine with aura is a U.S. MEC Category 4 (unacceptable health risk) contraindication for all combined hormonal contraceptives due to elevated ischemic stroke risk.
2
Step 2 — Eliminate Contraindicated Options

Given the Category 4 contraindication, all CHCs (COC, patch, ring) are eliminated from consideration. The estrogen component potentiates stroke risk in patients with migraine with aura through its prothrombotic effects—increased clotting factor synthesis and endothelial activation. We must select a progestin-only method.

All estrogen-containing methods (COC, patch, ring) are contraindicated. Remaining options: POP, DMPA, etonogestrel implant, LNG-IUS.
3
Step 3 — Match Patient Preferences to Pharmacokinetic Profile

The patient prefers to avoid daily dosing, which eliminates the traditional POP (norethindrone), which requires administration within a strict 3-hour window to maintain cervical mucus thickening. The etonogestrel subdermal implant (Nexplanon) provides continuous progestin release for 3 years with a Pearl Index < 0.1, making it the most effective reversible contraceptive available. DMPA is an alternative but is associated with delayed return to fertility and potential bone mineral density reduction with prolonged use.

Selected: Etonogestrel subdermal implant — 68 mg etonogestrel, effective for 3 years, no estrogen, no daily adherence requirement.
4
Step 4 — Address the Acne Concern

Etonogestrel is a metabolite of desogestrel, a gonane progestin with mild androgenic activity. While COCs containing anti-androgenic progestins (drospirenone, dienogest) or EE-driven SHBG elevation would more reliably improve acne, these are contraindicated in this patient. Counsel the patient that the implant may not improve—and could potentially worsen—acne. Adjunctive dermatological therapy (topical retinoids, spironolactone) should be discussed.

Acknowledge trade-off: etonogestrel implant maximizes contraceptive efficacy and safety but may not address acne. Refer to dermatology for complementary management.
5
Step 5 — Calculate and Communicate Efficacy

Using the Pearl Index formula: Pearl Index = (Number of pregnancies × 12 × 100) ÷ (Total months of exposure). In the pivotal trial, 6 pregnancies occurred over 20,648 woman-months of use. Pearl Index = (6 × 12 × 100) ÷ 20,648 = 7,200 ÷ 20,648 ≈ 0.35 per 100 woman-years. Communicate to the patient that this means fewer than 1 in 200 users will experience an unintended pregnancy over 3 years of use.

Pearl Index ≈ 0.35 per 100 woman-years. This is among the lowest failure rates of any reversible contraceptive method.

SECTION 7

Safety Profiles, Adverse Effects, and Drug Interactions

The safety profile of hormonal contraceptives is shaped primarily by the estrogen component's prothrombotic effects and the progestin's off-target receptor activity. Understanding these risks requires integrating knowledge of the coagulation cascade, hepatic protein synthesis, and steroid receptor pharmacology. The following table summarizes key adverse effects by method.

Adverse Effect	Mechanism	Most Associated Methods	Clinical Significance
VTE (DVT/PE)	EE increases hepatic synthesis of factors II, VII, X, fibrinogen; increases thrombin generation and APC resistance	All CHCs, especially high-dose EE (≥50 µg); patch (higher AUC); 3rd/4th-gen progestins (desogestrel, drospirenone)	Risk increases 3–6× over baseline; absolute risk still low (~3–9/10,000 woman-years vs. 1–5/10,000 baseline)
Arterial thromboembolism (MI, stroke)	EE-induced endothelial dysfunction, hypertension via RAAS activation (angiotensinogen increase)	CHCs in patients with additional risk factors: smoking ≥35 y/o, migraine with aura, hypertension	MEC Category 4; synergistic risk with smoking; absolute contraindication
Breakthrough bleeding	Insufficient estrogen to stabilize endometrium or progestin-induced atrophy with fragile vasculature	Progestin-only methods (implant, LNG-IUS initial months, DMPA); ultra-low-dose COCs	Common cause of discontinuation; typically improves over 3–6 months
Bone mineral density loss	DMPA suppresses ovarian estradiol production → estrogen-deficient state → increased osteoclast activity	DMPA (particularly >2 years of use)	FDA black box warning; largely reversible after discontinuation; clinical fracture risk data limited
Hepatic adenoma	EE stimulates hepatocyte proliferation; dose-dependent with prolonged high-dose exposure	COCs, especially older high-dose formulations	Rare but serious; risk increases >5 years use; regression common after discontinuation

Major adverse effects of hormonal contraceptives with underlying pharmacological mechanisms

⚠

Drug Interactions — CYP3A4 Inducers

EE and many progestins are substrates of CYP3A4. Potent CYP3A4 inducers—including rifampin, carbamazepine, phenytoin, phenobarbital, and St. John's wort—accelerate hepatic clearance of contraceptive steroids, reducing plasma levels below the ovulation-suppression threshold. Rifampin, in particular, reduces EE AUC by up to 64%. Patients taking these agents require non-hormonal or DMPA contraception, as DMPA achieves supraphysiological progestin levels less susceptible to enzyme induction.

✦

KEY TAKEAWAY

The safety profile of hormonal contraception is best understood through the lens of receptor pharmacology. The estrogen component drives hepatic prothrombotic and metabolic effects, while the progestin component's off-target receptor binding determines androgenic, glucocorticoid, and mineralocorticoid side effects. Just as an antibiotic's side effects are predictable from its spectrum of activity, a contraceptive's adverse effects are predictable from its receptor-binding profile. Rational prescribing requires matching the formulation's pharmacological fingerprint to the individual patient's risk factors.

SECTION 8

Connection to Advanced Concepts and Emerging Agents

Contemporary research in hormonal contraception is focused on reducing estrogen-related risks while maintaining efficacy, expanding non-oral delivery systems, and exploring entirely novel pharmacological targets beyond the classical steroid receptor axis. These advances build directly on the foundational pharmacology covered in this lesson.

Current Paradigm	Emerging Approach	Pharmacological Rationale
Ethinyl estradiol (EE) as estrogen component	Estetrol (E4) — fetal estrogen with selective tissue activity	E4 acts as an ERα agonist in the HPO axis (maintaining FSH suppression) but exhibits minimal hepatic first-pass effects, resulting in reduced impact on SHBG, coagulation factors, and lipids compared to EE
Daily oral dosing with user-dependent adherence	Biodegradable long-acting implants and microarray patches	Self-administered microneedle patches delivering levonorgestrel through sustained-release polymer matrices could achieve LARC-level efficacy without clinical insertion procedures
Steroid-based ovulation suppression	GnRH receptor antagonists (e.g., elagolix-derived agents)	Non-steroidal suppression of LH/FSH secretion at the pituitary level, potentially offering contraception with a distinct side-effect profile, though add-back estrogen may still be needed to prevent hypoestrogenic effects
Female-only hormonal methods	Male hormonal contraception (testosterone + progestin combinations)	Exogenous testosterone with a progestin (e.g., DMPA, nestorone) suppresses FSH/LH via negative feedback, reducing spermatogenesis to azoospermic or severely oligospermic levels

Comparison of current hormonal contraceptive paradigms with emerging pharmacological approaches

The trajectory of hormonal contraception development follows a consistent pharmacological theme: maximizing receptor selectivity to isolate the desired contraceptive effect while minimizing off-target binding that drives adverse events. Estetrol exemplifies this principle by exploiting tissue-selective estrogen receptor modulation, much as SERMs (tamoxifen, raloxifene) achieve tissue-selective effects in other clinical contexts. Students pursuing advanced study in reproductive pharmacology should explore the emerging literature on non-hormonal contraceptive targets, including sperm-specific ion channel blockers and oocyte maturation inhibitors, which represent a fundamental departure from the HPO-axis suppression paradigm that has dominated the field for over sixty years.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

Explain why combined oral contraceptives suppress ovulation but progestin-only pills (traditional norethindrone POP) may not. Reference the specific hormonal mechanisms and the HPO axis in your answer.

Show answer

COCs suppress ovulation because the combination of exogenous estrogen and progestin provides robust negative feedback on the HPO axis, suppressing both FSH and LH secretion sufficiently to prevent follicular maturation and abolish the mid-cycle LH surge. The estrogen component specifically suppresses FSH-driven folliculogenesis, while the progestin prevents the LH surge. Traditional norethindrone POPs deliver a lower progestin dose without estrogen, which is often insufficient to consistently suppress GnRH pulsatility and gonadotropin release. Instead, POPs rely primarily on peripheral mechanisms—cervical mucus thickening and endometrial atrophy—for their contraceptive effect, with ovulation still occurring in approximately 40–60% of cycles.

Question 2: BASIC CALCULATION

In a clinical trial of a new contraceptive method, 13,000 women used the method for a total of 156,000 woman-months of observation. During this time, 18 unintended pregnancies occurred. Calculate the Pearl Index and interpret the result.

Show answer

Applying the Pearl Index formula: Pearl Index = (Number of pregnancies × 12 × 100) ÷ Total months of exposure = (18 × 12 × 100) ÷ 156,000 = 21,600 ÷ 156,000 ≈ 0.14 per 100 woman-years. This Pearl Index of 0.14 indicates that approximately 0.14 out of every 100 women using this method will experience an unintended pregnancy per year of use. This failure rate is comparable to the etonogestrel implant and is markedly lower than typical-use COC rates (7–9), indicating excellent contraceptive efficacy. The low Pearl Index suggests either a very reliable mechanism of action or a delivery system that minimizes user-dependent adherence errors.

Question 3: INTERMEDIATE

A 32-year-old patient on a COC containing 30 µg ethinyl estradiol and 150 µg levonorgestrel is started on rifampin for latent tuberculosis. She asks whether her contraceptive will still work. Describe the pharmacokinetic interaction, explain the mechanism, and recommend an appropriate management strategy.

Show answer

Rifampin is one of the most potent inducers of CYP3A4, the primary hepatic enzyme responsible for the oxidative metabolism of ethinyl estradiol and levonorgestrel. Induction of CYP3A4 increases the rate of first-pass and systemic clearance of both contraceptive steroids, reducing their plasma AUC by as much as 64% for EE and 50% for levonorgestrel. This reduction can lower hormone levels below the threshold required for consistent ovulation suppression, substantially increasing pregnancy risk. The appropriate management is to counsel the patient that her COC is unreliable during rifampin therapy and for at least 28 days after its discontinuation. She should switch to a non-hormonal method (copper IUD) or DMPA injection, which achieves supraphysiological progestin levels that remain effective despite enhanced hepatic metabolism. Simply increasing the EE dose is not a recommended strategy because the interaction is too potent and unpredictable.

Question 4: APPLIED

A 22-year-old patient presents with a request for contraception. She has a BMI of 38 kg/m², a family history of VTE (mother with DVT at age 45), and reports significant premenstrual mood symptoms with heavy menstrual bleeding. She has no history of migraine. Using the U.S. MEC framework and pharmacological reasoning, develop a contraceptive plan that addresses her contraceptive needs while managing her menstrual symptoms.

Show answer

This patient has multiple risk factors for VTE: BMI ≥ 35 (MEC Category 3 for CHCs) and a positive family history of VTE, which further elevates her baseline thrombotic risk. While a family history alone is MEC Category 2, the combination with obesity pushes the risk-benefit balance unfavorably for CHCs. The estrogen component's prothrombotic effects—increased thrombin generation, elevated factor VII and fibrinogen, and increased APC resistance—would compound her existing risk. The 52 mg levonorgestrel IUS (Mirena) would be the optimal choice: it delivers progestin locally to the uterus, achieving high endometrial concentrations with minimal systemic absorption (serum LNG levels are approximately 150–200 pg/mL, far below oral LNG levels). This addresses her heavy menstrual bleeding through endometrial atrophy (80–90% reduction in blood loss), provides highly effective contraception (Pearl Index ≈ 0.1), and avoids systemic estrogen exposure. The LNG-IUS is MEC Category 1 for both obesity and VTE risk. For her premenstrual mood symptoms, which may relate to cyclical progesterone withdrawal, the LNG-IUS may provide partial relief, though referral for PMDD evaluation should be considered if symptoms persist.

Question 5: CRITICAL THINKING

The concept of 'typical-use' versus 'perfect-use' failure rates reveals a significant gap for user-dependent methods (COCs: 0.3% perfect-use vs. 7–9% typical-use) but virtually no gap for LARCs (implant: 0.05% vs. 0.05%). Critically analyze how this adherence gap should influence contraceptive counseling and public health policy. Consider pharmacokinetic, behavioral, and health-equity dimensions in your analysis.

Show answer

The adherence gap between perfect-use and typical-use failure rates reflects the fundamental pharmacokinetic vulnerability of short-acting methods: COCs require daily maintenance of plasma hormone levels above the ovulation-suppression threshold, and even brief interruptions (missed pills, GI illness, drug interactions) can permit follicular rescue and escape ovulation. LARCs eliminate this vulnerability by providing continuous drug delivery from a depot formulation, decoupling efficacy from daily user behavior. From a pharmacokinetic perspective, the etonogestrel implant maintains steady-state plasma levels of approximately 200–300 pg/mL throughout its 3-year lifespan, with no opportunity for adherence failure. Behaviorally, research consistently shows that adherence to daily medication regimens is challenging across all demographics, with nonadherence rates of 30–50% for chronic oral medications generally. This has profound health-equity implications: populations facing barriers to consistent pharmacy access, unpredictable work schedules, housing instability, or limited health literacy are disproportionately affected by adherence-dependent methods. LARC-first counseling—as endorsed by ACOG and the WHO—represents evidence-based policy that aligns pharmacological efficacy with real-world conditions. However, a critical nuance is that counseling must remain patient-centered and avoid coercion; the goal is informed choice with accurate efficacy data, not directive prescribing. Shared decision-making should present the full range of options with transparent discussion of typical-use failure rates, allowing patients to weigh efficacy against other priorities such as menstrual control, side-effect tolerance, reversibility timeline, and autonomy over method discontinuation.

SUMMARY

Hormonal Contraception — Key Concepts Review

Summary

Hormonal contraception exploits negative feedback on the HPO axis to suppress ovulation, with secondary mechanisms including cervical mucus thickening, endometrial atrophy, and altered tubal motility. Combined hormonal contraceptives pair a synthetic estrogen (most commonly ethinyl estradiol) with a progestin to suppress both FSH and LH, while progestin-only methods rely more heavily on peripheral mechanisms unless dosed at levels sufficient for ovulation suppression (e.g., DMPA). The Pearl Index quantifies contraceptive efficacy per 100 woman-years, and the gap between perfect-use and typical-use rates highlights the pharmacokinetic advantage of long-acting reversible contraceptives (LARCs).

Safety and side-effect profiles are determined by receptor cross-reactivity: the estrogen component drives prothrombotic and hepatic effects (VTE risk, hypertension), while progestin binding at androgen, glucocorticoid, and mineralocorticoid receptors determines androgenic, metabolic, and fluid-retention effects. Rational contraceptive selection integrates U.S. MEC eligibility criteria with patient-specific risk factors, preferences, and pharmacokinetic considerations such as CYP3A4-mediated drug interactions. Emerging agents like estetrol and novel delivery platforms aim to further dissociate contraceptive efficacy from adverse metabolic and thrombotic consequences.